medigraphic.com
ISSN 2683-1678 (Impreso)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2024, Número S1

Siguiente >>

Rev Latin Infect Pediatr 2024; 37 (S1)


Consenso de la Asociación Mexicana de Infectología Pediátrica (AMIP): prevención de la infección por virus sincitial respiratorio en México, 2024

Ortiz IFJ, González SN, Arias GE, Castillo BJI, Gutiérrez TIF, Laris GA, Lima RMV, Martínez ML, Moreno ES, Ochoa PU, Ordoñez OJ, Ortiz CB, Revelo CO, Tamez RO, Tena AG, Vázquez RM, Villa GM, Otero MF

Idioma: Español
Referencias bibliográficas: 98
Paginas: 6-28
Archivo PDF: 502.18 Kb.


RESUMEN

Introducción: las infecciones causadas por el virus sincicial respiratorio (VSR) están consideradas dentro de las principales causas de morbimortalidad en niños menores de dos años, así como de adultos mayores de 65 años. El objetivo del presente consenso es analizar, discutir y generar recomendaciones, sobre el beneficio e impacto de la inmunoprofilaxis sobre la carga de la enfermedad respiratoria por el VSR en México y América Latina. Material y métodos: mediante el modelo de consenso académico, se recopiló y analizó la bibliografía científica disponible de los temas considerados de actualidad o controversiales. Se siguió la recomendación de la Guía lineamientos para la elaboración de consensos y las recomendaciones y criterios útiles para la lectura crítica de los artículos seleccionados de la iniciativa europea AGREE, las recomendaciones generadas son presentadas bajo la escala GRADE. Se integraron equipos mixtos y representativos en los que participaron pediatras neonatólogos, ginecoobstetras, y pediatras infectólogos agremiados a la Asociación Mexicana de Infectología Pediátrica (AMIP). Los estudios y manuscritos utilizados para esta revisión fueron seleccionados usando las palabras clave: "respiratory syncytial virus", "vaccine", "monoclonal antibodies", "epidemiology", "safety and efficacy in vaccine", "compliance vaccine", entre otras. Se utilizaron los motores de búsqueda PubMed, Google Scholar, EMBASE, Cochrane, así como el apoyo de bibliotecas virtuales de las Universidades de Oxford, Harvard y Tecnológico de Monterrey. Se seleccionaron artículos dando prioridad aquéllos publicados de enero de 2019 a agosto de 2024; se incluyeron reportes más antiguos para marco de referencia, o por ser la información más sólida disponible. Se trabajó en una reunión presencial y dos virtuales, además de revisión de los textos generados por tres revisores externos al grupo de consenso. Resultados: se planteó un total de once temas relevantes o controvertidos, a los que se les realizó un análisis crítico de acuerdo con la evidencia encontrada y los resultados de la revisión de los artículos seleccionados fueron presentados con su nivel de recomendación de acuerdo con el sistema GRADE.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mazur NI, Terstappen J, Baral R, Bardají A, Beutels P, Buchholz UJ, et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2023; 23 (1): e2-21.

  2. Bénet T, Sánchez-Picot V, Messaoudi M, Chou M, Eap T, Wang J, et al. Microorganisms associated with pneumonia in children < 5 years of age in developing and emerging countries: the GABRIEL pneumonia multicenter, prospective, case-control study. Clin Infect Dis. 2017; 65 (4): 604-612. doi: 10.1093/cid/cix378.

  3. O'Brien KL, Baggett HC, Brooks WA, Feikin DR, Hammitt LL, Higdon MM, et al. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019; 394 (10200): 757-779. doi: 10.1016/S0140-6736(19)32010-0.

  4. Zhang XL, Zhang X, Hua W, Xie Z De, Liu HM, Zhang HL, et al. Expert consensus on the diagnosis, treatment, and prevention of respiratory syncytial virus infections in children. World J Pediatr. 2024; 20 (1): 11-25. doi: 10.1007/s12519-023-00777-9.

  5. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022; 399 (10340): 2047-2064. doi: 10.1016/S0140-6736(22)00478-0.

  6. Rosas-Salazar C, Chirkova T, Gebretsadik T, Chappell JD, Peebles RS, Dupont WD, et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study. Lancet. 2023; 401 (10389): 1669-1680. doi: 10.1016/S0140-6736(23)00811-5.

  7. Binns E, Tuckerman J, Licciardi PV, Wurzel D. Respiratory syncytial virus, recurrent wheeze and asthma: A narrative review of pathophysiology, prevention and future directions. J Paediatr Child Health. 2022; 58 (10): 1741-1746. doi: 10.1111/jpc.16197.

  8. Kitcharoensakkul M, Bacharier LB, Schweiger TL, Wilson B, Goss CW, Lew D et al. Lung function trajectories and bronchial hyperresponsiveness during childhood following severe RSV bronchiolitis in infancy. Pediatr Allergy Immunol. 2021; 32 (3): 457-464. doi: 10.1111/pai.13399.

  9. Daniels D. A review of respiratory syncytial virus epidemiology among children: linking effective prevention to vulnerable populations. J Pediatric Infect Dis Soc. 2024; 13 (Supplement_2): S131-S136.

  10. Shi T, Balsells E, Wastnedge E, Singleton R, Rasmussen ZA, Zar HJ, et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis. J Glob Health. 2015; 5 (2): 020416.

  11. Shi T, Vennard S, Jasiewicz F, Brogden R, Nair H. Disease burden estimates of respiratory syncytial virus related acute respiratory infections in adults with comorbidity: a systematic review and meta-analysis. J Infect Dis. 2022; 226 (Suppl 1): S17-S21.

  12. Falsey AR, McElhaney JE, Beran J, Van Essen GA, Duval X, Esen M, et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis. 2014; 209 (12): 1873-1881.

  13. Midgley CM, Haynes AK, Baumgardner JL, Chommanard C, Demas SW, Prill MM, et al. Determining the seasonality of respiratory syncytial virus in the United States: the impact of increased molecular testing. J Infect Dis. 2017; 216 (3): 345-355.

  14. Cantú-Flores K, Rivera-Alfaro G, Muñoz-Escalante JC, Noyola DE. Global distribution of respiratory syncytial virus A and B infections: a systematic review. Pathog Glob Health. 2022; 116 (7): 398-409.

  15. Goya S, Ruis C, Neher RA, Meijer A, Aziz A, Hinrichs AS, et al. Standardized phylogenetic classification of human respiratory syncytial virus below the subgroup level. Emerg Infect Dis. 2024; 30 (8): 1631-1641. doi: 10.3201/eid3008.240209.

  16. Kaler J, Hussain A, Patel K, Hernandez T, Ray S. Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation. Cureus. 2023; 15 (3): e36342.

  17. Ferrario DC, Califano DG, Durán P, Maccarone DM, Miceli DI, Manterola A, et al. Lineamientos para la elaboración de Consensos Guidelines for planning consensus Sociedad Argentina de Pediatría Subcomisiones, Comités y Grupos de Trabajo. Arch Argent Pediatr. 2012; 110 (2): 163-167. doi: 10.5546/aap.2012.163.

  18. Original AGREE instrument. Agreetrust.org. Available in: https://www.agreetrust.org/resource-centre/the-original-agree-instrument/

  19. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64 (4): 383-394.

  20. Manterola C, Asenjo-Lobos C, Otzen T. Jerarquización de la evidencia: niveles de evidencia y grados de recomendación de uso actual. Rev Chil Infectol. 2014; 31 (6): 705-718.

  21. Giersing BK, Vekemans J, Nava S, Kaslow DC, Moorthy V. Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016. Vaccine. 2019; 37 (50): 7315-7327.

  22. Zhao M, Zheng ZZ, Chen M, Modjarrad K, Zhang W, Zhan LT, et al. Discovery of a prefusion respiratory syncytial virus F-specific monoclonal antibody that provides greater in vivo protection than the murine precursor of palivizumab. J Virol. 2017; 91 (15): 176-193.

  23. Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nature Reviews Microbiology 2019 17:4. 2019; 17 (4): 233-245.

  24. Graham BS. The journey to RSV vaccines - Heralding an era of structure-based design. N Engl J Med. 2023; 388 (7): 579-581.

  25. Mejias A, Ramilo O. RSV prevention within reach for older infants and toddlers: the role of active immunization. J Pediatric Infect Dis Soc. 2024; 13 (Supplement_2): S125-S130. doi: 10.1093/jpids/piae049.

  26. Hammitt LL, Dagan R, Yuan Y, Cots MB, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022; 386 (9): 837-846. doi: 10.1056/NEJMoa2110275.

  27. Muller WJ, Madhi SA, Seoane-Nuñez B, Baca-Cots M, Bosheva M, Dagan R, et al. Nirsevimab for prevention of rsv in term and late-preterm infants. N Engl J Med. 2023; 388 (16): 1533-1534.

  28. Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023; 388 (7): 595-608. doi: 10.1056/NEJMoa2209604.

  29. Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, et al. Efficacy and safety of an mRNA-based RSV preF vaccine in older adults. N Engl J Med. 2023; 389 (24): 2233-2244. doi: 10.1056/NEJMoa2307079.

  30. Walsh EE, Pérez-Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023; 388 (16): 1465-1477. doi: 10.1056/NEJMoa2213836.

  31. Kampmann B, Madhi SA, Munjal I, Simoes EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023; 388 (16): 1451-1464. doi: 10.1056/NEJMoa2216480.

  32. Rao S, Armistead I, Messacar K, Alden NB, Schmoll E, Austin E, et al. Shifting epidemiology and severity of Respiratory Syncytial Virus in children during the COVID-19 pandemic. JAMA Pediatr. 2023; 177 (7): 730-732.

  33. Esparza-Miranda LA, Juárez-Tobías S, Muñoz-Escalante JC, Oliva-Jara UA, Cadena-Mota S, Wong-Chew RM, et al. Clinical and epidemiologic characteristics of infants hospitalized with Respiratory Syncytial Virus infection during the 2022-2023 season in Mexico. Pediatr Infect Dis J. 2023; 42 (10): E382-E384.

  34. Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013; 132 (2): e341-e348.

  35. Haerskjold A, Kristensen K, Kamper-Jorgensen M, Nybo-Andersen AM, Ravn H, Graff Stensballe L. Risk factors for hospitalization for respiratory syncytial virus infection: a population-based cohort study of Danish children. Pediatr Infect Dis J. 2016; 35 (1): 61-65.

  36. Korsten K, Adriaenssens N, Coenen S, Butler C, Ravanfar B, Rutter H, et al. Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study. Eur Respir J. 2021; 57 (4): 2002688.

  37. CDC. Respiratory Syncytial Virus (RSV). Available from: https://www.cdc.gov/rsv/index.html

  38. Langedijk AC, Bont LJ. Respiratory syncytial virus infection and novel interventions. Nat Rev Microbiol. 2023; 21 (11): 734-749.

  39. Sheshadri A, Evans SE. Respiratory syncytial virus vaccination in the adult pulmonary patient. Chest. 2024: S0012-3692(24)00705-0.

  40. Wang X, Li Y, Shi T, Bont LJ, Chu HY, Zar HJ, et al. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data. Lancet. 2024; 403 (10433): 1241-1253.

  41. Wong-Chew RM, García-León ML, Noyola DE, Pérez-González LF, Gaitán-Meza J, Villaseñor-Sierra A, et al. Respiratory viruses detected in Mexican children younger than 5 years old with community-acquired pneumonia: a national multicenter study. Int J Infect Dis. 2017; 62: 32-38.

  42. Ortiz-Hernández AA, Nishimura KK, Noyola DE, Moreno-Espinosa S, Gamiño A, Galindo-Fraga A, et al. "Differential risk of hospitalization among single virus infections causing influenza?like illnesses". Influenza Other Respir Viruses. 2019; 13 (1): 36.

  43. Lipp MA, Empey KM. Recent advances in the prevention of respiratory syncytial virus in pediatrics. Curr Opin Pediatr. 2024; 36 (2): 182-189.

  44. Rha B, Curns AT, Lively JY, Campbell AP, Englund JA, Boom JA, et al. Respiratory syncytial virus-associated hospitalizations among young children: 2015-2016. Pediatrics. 2020; 146 (1): e20193611.

  45. Glatman-Freedman A, Kaufman Z, Applbaum Y, Dichtiar R, Steiman A, Gordon ES, et al. Respiratory Syncytial Virus hospitalization burden: a nation-wide population-based analysis, 2000-2017. J Infect. 2020; 81 (2): 297-303.

  46. Duan Y, Jiang M, Huang Q, Jia M, Yang W, Feng L. Incidence, hospitalization, and mortality in children aged 5 years and younger with respiratory syncytial virus-related diseases: a systematic review and meta-analysis. Influenza Other Respi Viruses. 2023; 17 (5): e13145. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/irv.13145

  47. Mazur NI, Lowensteyn YN, Willemsen JE, Gill CJ, Forman L, Mwananyanda LM, et al. Global Respiratory Syncytial Virus-related infant community deaths. Clin Infect Dis. 2021; 73 (Supplement_3): S229-S237. doi: 10.1093/cid/ciab528.

  48. Blau DM, Baillie VL, Els T, Mahtab S, Mutevedzi P, Keita AM, et al. Deaths attributed to Respiratory Syncytial Virus in young children in high–mortality rate settings: report from Child Health and Mortality Prevention Surveillance (CHAMPS). Clin Infect Dis. 2021; 73 (Supplement_3): S218-S228. doi: 10.1093/cid/ciab509.

  49. Gentile A, Lucion MF, Del Valle Juarez M, Areso MS, Bakir J, Viegas M, et al. Burden of Respiratory Syncytial Virus disease and mortality risk factors in Argentina: 18 years of active surveillance in a children's hospital. Pediatr Infect Dis J. 2019; 38 (6): 589-594.

  50. Geoghegan S, Erviti A, Caballero MT, Vallone F, Zanone SM, Losada JV, et al. Mortality due to Respiratory Syncytial Virus burden and risk factors. Am J Respir Crit Care Med. 2017; 195 (1): 96-103.

  51. Martinón-Torres F, Carmo M, Platero L, Drago G, López-Belmonte JL, Bangert M, et al. Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study. BMC Infect Dis. 2022; 22 (1): 759.

  52. Martinón-Torres F, Carmo M, Platero L, Drago G, López-Belmonte J, Bangert M, et al. Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015-2018. BMC Infect Dis. 2023; 23 (1): 385.

  53. Dovizio M, Veronesi C, Bartolini F, Cavaliere A, Grego S, Pagliaro R, et al. Clinical and economic burden of respiratory syncytial virus in children aged 0-5 years in Italy. Ital J Pediatr. 2024; 50 (1): 1-11.

  54. Do LAH, Vodicka E, Nguyen A, Le TNK, Nguyen TTH, Thai QT, et al. Estimating the economic burden of respiratory syncytial virus infections in infants in Vietnam: a cohort study. BMC Infect Dis. 2023; 23 (1): 73.

  55. Chirikov VV, Simoes EAF, Kuznik A, Kwon Y, Botteman M. Economic-burden trajectories in commercially insured US infants with Respiratory Syncytial Virus infection. J Infect Dis. 2020; 221 (8): 1244-1255. doi: 10.1093/infdis/jiz160.

  56. Mould-Quevedo JF, Contreras-Hernández I, Martínez-Valverde S, Villasis-Keever MA, Granados-García VM, Salinas-Escudero G, et al. Direct medical costs of treating Mexican children under 2 years of age with Respiratory Syncytial Virus. Bol Med Hosp Infant Mex. 2012; 69 (2): 111-115.

  57. Comas-García A, Aguilera-Martínez JI, Escalante-Padrón FJ, Lima-Rogel V, Gutierrez-Mendoza LM, Noyola DE. Clinical impact and direct costs of nosocomial respiratory syncytial virus infections in the neonatal intensive care unit. Am J Infect Control. 2020; 48 (9): 982-986.

  58. Rocha-Filho CR, Ramalho GS, Martins JWL, Lucchetta RC, Pinto ACPN, da Rocha AP, et al. Economic burden of respiratory syncytial and parainfluenza viruses in children of upper-middle-income countries: a systematic review. J Pediatr (Rio J). 2023; 99 (6): 537-545.

  59. Li X, Willem L, Antillon M, Bilcke J, Jit M, Beutels P. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. BMC Med. 2020; 18 (1): 82.

  60. Moreno C, Bardach A, Palermo MC, Sandoval MM, Baumeister E, Ruvinsky S, et al. Economic burden of respiratory syncytial virus disease in Latin America: a systematic review. Hum Vaccin Immunother. 2024; 20 (1): 2381298. doi: 10.1080/21645515.2024.2381298.

  61. Garegnani L, Styrmisdóttir L, Roson-Rodriguez P, Escobar-Liquitay CM, Esteban I, Franco JVA. Palivizumab for preventing severe Respiratory Syncytial Virus (RSV) infection in children. Cochrane Database Syst Rev. 2021; 11 (11): CD013757.

  62. Resch B. Product review on the monoclonal antibody palivizumab for prevention of Respiratory Syncytial Virus infection. Hum Vaccin Immunother. 2017; 13 (9): 2138-2149.

  63. Posner J, Barrington P, Brier T, Datta-Mannan A. Monoclonal antibodies: past, present and future. Handb Exp Pharmacol. 2019; 260: 81-141.

  64. Connor EM. Palivizumab, a humanized Respiratory Syncytial Virus monoclonal antibody, reduces hospitalization from Respiratory Syncytial Virus infection in high-risk infants. Pediatrics. 1998; 102 (3): 531-537.

  65. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, et al. Palivizumab prophylaxis reduces hospitalization due to Respiratory Syncytial Virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003; 143 (4): 532-540.

  66. Sun M, Lai H, Na F, Li S, Qiu X, Tian J, et al. Monoclonal antibody for the prevention of Respiratory Syncytial Virus in infants and children: a systematic review and network meta-analysis. JAMA Netw Open. 2023; 6 (2): e230023-e230023.

  67. Gonzales T, Bergamasco A, Cristarella T, Goyer C, Wojdyla M, Oladapo A, et al. Effectiveness and safety of palivizumab for the prevention of serious lower respiratory tract infection caused by Respiratory Syncytial Virus: a systematic review. Am J Perinatol. 2024; 41 (S 01): E1107-E1115.

  68. Maheshwari A, Singh S, Namazova I, Benjamin JT, Wang Y. Respiratory Syncytial Virus infections in neonates: a persisting problem. Newborn (Clarksville, Md). 2023; 2 (3): 222-234.

  69. Brady MT, Byington CL, Davies HD, Edwards KM, Jackson MA, Maldonado YA, et al. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for Respiratory Syncytial Virus infection. Pediatrics. 2014; 134 (2): 415-420.

  70. Caserta MT, O'Leary ST, Muñoz FM, Ralston SL. Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for Respiratory Syncytial Virus infection. Pediatrics. 2023; 152 (1): e2023061803.

  71. Committee on Infectious Diseases, American Academy of Pediatrics. Red Book: 2024-2027 Report of the Committee on infectious diseases. Kimberlin DW, Banerjee R, Barnett ED, Lynfield R, Sawyer MH. American Academy of Pediatrics345 Park Blvd, Itasca, IL 60143; 2024.

  72. Sociedad Latinoamericana de Infectología Pediátrica. Virus respiratorio sincitial en América Latina y el Caribe. Revisión de la literatura y perspectiva regional consenso de la Sociedad Latinoamericana De Infectología Pediátrica. SLIPE. 2024. p. 39-40.

  73. Noor A, Krilov LR. A historical perspective on Respiratory Syncytial Virus prevention: a journey spanning over half a century from the setback of an inactive vaccine candidate to the success of passive immunization strategy. J Pediatric Infect Dis Soc. 2024; 13 (Supplement_2): S103-S109.

  74. Domachowske JB, Anderson EJ, Goldstein M. The future of Respiratory Syncytial Virus disease prevention and treatment. Infect Dis Ther. 2021; 10 (1): 47-60.

  75. Viguria N, Navascués A, Juanbeltz R, Echeverría A, Ezpeleta C, Castilla J. Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children. Hum Vaccin Immunother. 2021; 17 (6): 1867.

  76. Ruiz-Galiana J, Cantón R, Ramos PDL, García-Botella A, García-Lledó A, Hernández-Sampelayo T, et al. Respiratory Syncytial Virus: a new era. Rev Esp Quimioter. 2024; 37 (2): 134-148.

  77. World Health Organization. WHO preferred product characteristics for Respiratory Syncytial Virus (RSV) vaccines. 2017. Available from: http://apps.who.int/bookorders.

  78. Gunatilaka A, Giles ML. Maternal RSV vaccine development. Where to from here? Hum Vaccin Immunother. 2021; 17 (11): 4542-4548.

  79. Madhi SA, Polack FP, Piedra PA, Muñoz FM, Trenholme AA, Simoes EAF, et al. Respiratory Syncytial Virus vaccination during pregnancy and effects in infants. N Engl J Med. 2020; 383 (5): 426-439.

  80. Dieussaert I, Hyung Kim J, Luik S, Seidl C, Pu W, Stegmann JU, et al. RSV Prefusion F protein-based maternal vaccine - Preterm birth and other outcomes. N Engl J Med. 2024; 390 (11): 1009-1021.

  81. Muñoz FM, Swamy GK, Hickman SP, Agrawal S, Piedra PA, Glenn GM, et al. Safety and immunogenicity of a Respiratory Syncytial Virus Fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. J Infect Dis. 2019; 220 (11): 1802-1815.

  82. FDA. September 12, 2023 Summary basis for regulatory action - ABRYSVO. 2023. Available in: https://www.fda.gov/media/172126/download

  83. Schwarz TF, Johnson C, Grigat C, Apter D, Csonka P, Lindblad N, et al. Three dose levels of a maternal Respiratory Syncytial Virus vaccine candidate are well tolerated and immunogenic in a randomized trial in nonpregnant women. J Infect Dis. 2022; 225 (12): 2067-2076.

  84. Simoes EAF, Center KJ, Tita ATN, Swanson KA, Radley D, Houghton J, et al. Prefusion F protein-based Respiratory Syncytial Virus immunization in pregnancy. N Engl J Med. 2022; 386 (17): 1615-1626.

  85. Bebia Z, Reyes O, Jeanfreau R, Kantele A, De Leon RG, Sánchez MG, et al. Safety and immunogenicity of an investigational Respiratory Syncytial Virus vaccine (RSVPreF3) in mothers and their infants: a phase 2 randomized trial. J Infect Dis. 2023; 228 (3): 299-310.

  86. Phijffer EW, de Bruin O, Ahmadizar F, Bont LJ, Van der Maas NAT, Sturkenboom MCJM, et al. Respiratory Syncytial Virus vaccination during pregnancy for improving infant outcomes. Cochrane Database Syst Rev. 2024; 2024 (5).

  87. Respiratory Syncytial Virus: the green book, Chapter 27a, UK Health Security Agency. Gateway number 2024320. Available in: https://assets.publishing.service.gov.uk/media/669a5e37ab418ab05559290d/Green-book-chapter-27a-RSV-18_7_24.pdf

  88. Abrysvo [Internet]. European Medicines Agency (EMA). [citado el 10 de octubre de 2024]. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo

  89. ACOG. Maternal Respiratory Syncytial Virus Vaccination. 2024. Available in: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2023/09/maternal-respiratory-syncytial-virus-vaccination

  90. Dagan R, Hammitt LL, Nuñez BS, Cots MB, Bosheva M, Madhi SA, et al. Infants receiving a single dose of nirsevimab to prevent RSV do not have evidence of enhanced disease in their second RSV season. J Pediatric Infect Dis Soc. 2024; 13 (2): 144.

  91. Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, et al. Nirsevimab for prevention of hospitalizations due to RSV in Infants. N Engl J Med. 2023; 389 (26): 2425-2435.

  92. Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020; 383 (5): 415-425.

  93. Domachowske J, Madhi SA, Simoes EAF, Atanasova V, Cabañas F, Furuno K, et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med. 2022; 386 (9): 892-894.

  94. Ares-Gómez S, Mallah N, Santiago-Pérez MI, Pardo-Seco J, Pérez-Martínez O, Otero-Barrós MT, et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for Respiratory Syncytial Virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis. 2024; 24 (8): 817-828.

  95. Coma E, Martinez-Marcos M, Hermosilla E, Mendioroz J, Reñé A, Fina F, et al. Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain). Arch Dis Child. 2024; 109 (9): 736-741.

  96. Moline HL, Tannis A, Toepfer AP, Williams JV, Boom JA, Englund JA, et al. Early estimate of nirsevimab effectiveness for prevention of Respiratory Syncytial Virus-associated hospitalization among infants entering their first Respiratory Syncytial Virus season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024; 73 (9): 209-214.

  97. Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sánchez PJ, et al. Use of nirsevimab for the prevention of Respiratory Syncytial Virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023; 72 (34): 920-925.

  98. ClinicalTrials.gov. Efficacy and safety of clesrovimab (MK-1654) in infants (MK-1654-004). 2024. Available from: https://clinicaltrials.gov/study/NCT04767373




2020     |     www.medigraphic.com